Development of Nitric oxide traffic protein as a novel drug againstischemic diseases

• Project/Area Number: 22790162
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Single-year Grants
• Research Field: Medical pharmacy
• Research Institution: Kumamoto University
• Principal Investigator: ISHIMA Yu 熊本大学, 薬学部, 助教 (00457590)
• Project Period (FY): 2010 – 2012
• Project Status: Completed (Fiscal Year 2012)
• Budget Amount: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000); Fiscal Year 2012: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2011: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2010: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 薬物動態学 / ドラッグデリバリーシステム / ヒト血清アルブミン / 一酸化窒素 / 虚血性疾患 / S-ニトロソ化 / 臓器移植 / NOトラフィックタンパク質 / 遺伝子組換え / 虚血再灌流障害 / S-ニトロン化

Research Abstract

S-Nitrosated human serum albumin (SNO-HSA) is useful in preventing liverischemia/reperfusion injury, and SNO-HSA should thus be able to prevent cell injury duringliver transplantation. However, the potential protective effect of SNO-HSA on acombination of cold and warm ischemia, which is obligatory when performing livertransplantation, has not been examined. Our results indicate that a combination of SNO-HSAand UW solution can be used to prevent the two types of ischemia. Therefore, SNO-HSA-addedUW solution could be very useful in transplantation, because the previously imposedconstraints on preservation time can be removed. This is a great advantage in a situationas the present one with increased utilization of scarce donor organs for more recipients

Research Products

• [Journal Article] UW solution improved with highanti-apoptotic activity byS-nitrosated human serum albumin (2013)
  • Author(s): IshimaY, Shinagawa T, Yoneshige S,Kragh-Hansen U, Ohya Y, Inomata Y,Kai T, Otagiri M, Maruyama T.
  • Journal Title: Nitric Oxide Volume: 30 Pages: 36-42
  • Peer Reviewed
• [Journal Article] Albumin domain II mutant with highbilirubin binding affinity has agreat potential as serum bilirubinexcretion enhancer forhyperbilirubinemia treatment (2013)
  • Author(s): Minomo A, Ishima Y, ChuangVT, Suwa Y, Kragh-Hansen U, NarisokoT, Morioka H, Maruyama T, Otagiri M
  • Journal Title: Biochim Biophys Acta Volume: 1830 Pages: 2917-23
  • Peer Reviewed
• [Journal Article] p-Cresyl sulfate causes renaltubular cell damage by inducingoxidative stress by activation ofNADPH oxidase (2013)
  • Author(s): Watanabe H, Miyamoto Y,Honda D, Tanaka H, Wu Q, Endo M,Noguchi T, Kadowaki D, Ishima Y,Kotani S, Nakajima M, Kataoka K,Kim-Mitsuyama S, Tanaka M, FukagawaM, Otagiri M, Maruyama T.
  • Journal Title: Kidney Int Volume: 83 Pages: 582-92
  • Peer Reviewed
• [Journal Article] A human serum albumin-thioredoxinfusion protein preventsexperimental contrast-inducednephropathy (2013)
  • Author(s): Kodama A, Watanabe H, TanakaR, Tanaka H, Chuang VT, Miyamoto Y,Wu Q, Endo M, Hamasaki K, Ishima Y,Fukagawa M, Otagiri M, Maruyama T.
  • Journal Title: Kidney Int Volume: 83 Pages: 446-54
  • Peer Reviewed
• [Journal Article] S-nitrosated α-1-acidglycoprotein kills drug-resistantbacteria and aids survival in sepsis (2013)
  • Author(s): WatanabeK, Ishima Y, Akaike T, Sawa T, KurodaT, Ogawa W, Watanabe H, Suenaga A,Kai T, Otagiri M, Maruyama T.
  • Journal Title: FASEB J Volume: 27 Pages: 391-8
  • Peer Reviewed
• [Journal Article] UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin. (2013)
  • Author(s): Ishima Y
  • Journal Title: Nitric Oxide. Volume: 印刷中 Pages: 36-42
  • DOI: 10.1016/j.niox.2013.01.004
  • Peer Reviewed
• [Journal Article] Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment. (2013)
  • Author(s): Minomo A
  • Journal Title: Biochim Biophys Acta. Volume: 印刷中 Issue: 4 Pages: 141-8
  • DOI: 10.1016/j.bbagen.2013.01.006
  • Peer Reviewed
• [Journal Article] p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress byactivation of NADPH oxidase. (2013)
  • Author(s): Hiroshi Watanabe^*, Yohei Miyamoto^*,Daisuke Honda, Hisae Tariaka, Qiong Wu,Masayuki Endo, Tsuyoshi Noguchi, DaisukeKadowaki, Yu Ishima, Shunsuke Kotani,Makoto Nakajima, Keiichiro Kataoka,Shokei Kim-Mitsuyama, Motoko Tanaka,Masafumi Fukagawa, Masaki Otagiri, ToruMaruyama. (^*:Hiroshi Watanabe and YoheiMiyamoto contributed equally to this work.)
  • Journal Title: Kidney International Volume: (印刷中) Issue: 4 Pages: 582-592
  • DOI: 10.1038/ki.2012.448
  • Peer Reviewed
• [Journal Article] A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy. (2013)
  • Author(s): Kodama A
  • Journal Title: Kidney Int. Volume: 印刷中 Issue: 3 Pages: 446-54
  • DOI: 10.1038/ki.2012.429
  • Peer Reviewed
• [Journal Article] S-nitrosylated a-l-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis (2013)
  • Author(s): Watanabe K, Ishima Y, Akaike T, Sawa T, Kuroda T, Ogawa W, Watanabe H, Suenaga A, Kai T, Otagiri M, and Maruyama T.
  • Journal Title: FASEB J Volume: 27 Issue: 1 Pages: 391-398
  • DOI: 10.1096/fj.12-217794
  • Peer Reviewed
• [Journal Article] Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin. (2013)
  • Author(s): Watanabe H
  • Journal Title: Biochim Biophys Acta. Volume: 40 Issue: 7 Pages: 1423-8
  • DOI: 10.1124/dmd.112.045617
  • Peer Reviewed
• [Journal Article] Elucidation of the therapeuticenhancer mechanism ofpoly-S-nitrosated human serum albuminagainst multidrug-resistant tumor inanimal models (2012)
  • Author(s): Ishima Y, Hara M,Kragh-Hansen U, Inoue A, Suenaga A,Kai T, Watanabe H, Otagiri M, MaruyamaT.
  • Journal Title: J Control Release Volume: 164 Pages: 1-7
  • Peer Reviewed
• [Journal Article] A uremic toxin,3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage toproximal tubular cells via thegeneration of a radical intermediate (2012)
  • Author(s): Miyamoto Y, Ishima Y,Otagiri M, Maruyama T.
  • Journal Title: Biochem Pharmacol Volume: 84 Pages: 1207-1214
  • Peer Reviewed
• [Journal Article] Interaction between twosulfate-conjugated uremic toxins,p-cresyl sulfate and indoxyl sulfate,during binding with human serumalbumin (2012)
  • Author(s): Watanabe H, Miyamoto Y,Ishima Y, Otagiri M, Maruyama T.
  • Journal Title: Drug Metab Dispos Volume: 40 Pages: 1423-1428
  • Peer Reviewed
• [Journal Article] S-guanylation of human serum albuminis a unique posttranslationalmodification and results in a novelclass of antibacterial agents (2012)
  • Author(s): Ishima Y,Akaike T, Maruyama T, Otagiri M.
  • Journal Title: J PharmSci Volume: 101 Pages: 3222-3229
  • Peer Reviewed
• [Journal Article] Quantitative evaluation of the role ofcysteine and methionine residues inthe antioxidant activity of humanserum albumin using recombinantmutants (2012)
  • Author(s): Ishima Y, Maruyama T, Otagiri M.
  • Journal Title: IUBMB Life. Volume: 64 Pages: 450-454
  • Peer Reviewed
• [Journal Article] S-Nitrosated human serum albumindimer is not only a novel anti-tumordrug but also a potentiator foranti-tumor drugs with augmented EPReffects (2012)
  • Author(s): Ishima Y, Maeda H, MaruyamaT, Otagiri M.
  • Journal Title: Bioconjug Chem. Volume: 23 Pages: 264-271
  • Peer Reviewed
• [Journal Article] Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models. (2012)
  • Author(s): Ishima Y
  • Journal Title: J Control Release. Volume: 164 Issue: 1 Pages: 1-7
  • DOI: 10.1016/j.jconrel.2012.10.003
  • Peer Reviewed
• [Journal Article] A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate. (2012)
  • Author(s): Yohei Miyamoto, Yasunori Katsumi Mera, Hiroshi Watanabe, Daisuke Kadowaki, Yu Ishima, Victor Tuan Giam Chuang, Keizo Sato, Masaki Otagiri, Toru Maruyama.
  • Journal Title: Biochemical Pharmacology Volume: 84 Issue: 9 Pages: 1207-1214
  • DOI: 10.1016/j.bcp.2012.07.033
  • Peer Reviewed
• [Journal Article] S-Guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents (2012)
  • Author(s): Ishima Y, Hoshino H, Shinagawa T, Watanabe K, Akaike T, Sawa T, Kragh-Hansen U, Kai T, Watanabe H, Maruyama T, and Otagiri M
  • Journal Title: J. Pharm. Sci Volume: 101 Issue: 9 Pages: 3222-3229
  • DOI: 10.1002/jps.23143
  • Peer Reviewed
• [Journal Article] Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants (2012)
  • Author(s): Iwao Y
  • Journal Title: IUBMB Life Volume: 64 Issue: 5 Pages: 450-454
  • DOI: 10.1002/iub.567
  • Peer Reviewed
• [Journal Article] S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects (2012)
  • Author(s): Ishima Y
  • Journal Title: Bioconjug Chem Volume: 23 Issue: 2 Pages: 264-271
  • DOI: 10.1021/bc2005363
  • Peer Reviewed
• [Journal Article] Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display (2012)
  • Author(s): Minomo A
  • Journal Title: FEBS J Volume: 278 Pages: 4100-4111
  • Peer Reviewed
• [Journal Article] Biological characteristics of twolysines on human serum albumin in thehigh-affinity binding of 4Z,15Z-bilirubin-IX α revealed byphage display (2011)
  • Author(s): Minomo A, Ishima Y,Kragh-Hansen U, Maruyama T, OtagiriM.
  • Journal Title: FEBS J Volume: 278 Pages: 4100-4111
  • Peer Reviewed
• [Journal Article] Cellular uptake mechanisms andresponses to NO transferred frommono- and poly-S-nitrosated humanserum albumin (2011)
  • Author(s): Ishima Y, Yoshida F,Akaike T, Maruyama T, Otagiri M.
  • Journal Title: Free Radic Res Volume: 45 Pages: 1196-1206
  • Peer Reviewed
• [Journal Article] Human serum albumin-thioredoxinfusion protein with long bloodretention property is effective insuppressing lung injury (2011)
  • Author(s): Furukawa M, Chuang VT, Ishima Y,Maruyama T, Otagiri M.
  • Journal Title: J ControlRelease Volume: 154 Pages: 189-195
  • Peer Reviewed
• [Journal Article] Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin (2011)
  • Author(s): Yu Ishima., et al
  • Journal Title: Free Radical Research Volume: 45 Issue: 10 Pages: 1196-1206
  • DOI: 10.3109/10715762.2011.606814
  • Peer Reviewed
• [Journal Article] Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury (2011)
  • Author(s): Furukawa M
  • Journal Title: J Control Release Volume: 154 Issue: 2 Pages: 189-195
  • DOI: 10.1016/j.jconrel.2011.05.013
  • Peer Reviewed
• [Journal Article] Albumin fusion of thioredoxin--theproduction and evaluation of itsbiological activity for potentialtherapeutic applications (2010)
  • Author(s): kuta S,Chuang VT, Ishima Y, Maruyama T,Otagiri M.
  • Journal Title: J ControlRelease Volume: 147 Pages: 17-23
  • Peer Reviewed
• [Journal Article] The critical role of nitric oxidesignaling, via proteinS-guanylation and nitrated cyclicGMP, in the antioxidant adaptiveresponse (2010)
  • Author(s): Fujii S, Okamoto T,Ahtesham AK, Ishima Y, Motohashi H,Yamamoto M, Akaike T.
  • Journal Title: J Biol Chem Volume: 285 Pages: 23970-23984
  • Peer Reviewed
• [Journal Article] One-step preparation ofS-nitrosated human serum albuminwith high biological activities (2010)
  • Author(s): Ishima Y, Hiroyama S, Kragh-HansenU, Maruyama T, Sawa T, Akaike T, KaiT, Otagiri M.
  • Journal Title: Nitric Oxide Volume: 23 Pages: 121-127
  • Peer Reviewed
• [Journal Article] Genetically engineered mannosylatedhuman serum albumin as a versatilecarrier for liver-selectivetherapeutics (2010)
  • Author(s): Hirata K, Maruyama T,Watanabe H, Ishima Y, Hashida M,Otagiri M.
  • Journal Title: J Control Release Volume: 145 Pages: 9-16
  • Peer Reviewed
• [Journal Article] Hirata K, Maruyama T,Watanabe H, Ishima Y, Hashida M,Otagiri M. (2010)
  • Author(s): Katayama N, Nakajou K, Ishima Y, IkutaS, Yokoe JI, Yoshida F, Suenaga A,Maruyama T, Kai T, Otagiri M.
  • Journal Title: Nitric Oxide Volume: 22 Pages: 259-265
  • Peer Reviewed
• [Journal Article] Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells. (2010)
  • Author(s): Katayama N
  • Journal Title: Nitric Oxide Volume: 22 Pages: 259-265
  • Peer Reviewed
• [Journal Article] The critical role of nitric oxide signaling, via protein S-guanylation and nitrated cyclic GMP, in the antioxidant adaptive response. (2010)
  • Author(s): Fujii S
  • Journal Title: J Biol Chem Volume: 285 Pages: 23970-23984
  • Peer Reviewed
• [Journal Article] One-step preparation of S-nitrosated human serum albumin with high biological activities. (2010)
  • Author(s): Ishima Y
  • Journal Title: Nitric Oxide Volume: 23 Pages: 121-127
  • NAID: 120002971552
  • Peer Reviewed
• [Presentation] Poly-S-nitrosated Human Serum Albumin inhibits the Expression of P-glycoprotein Transporter in Human Multidrug-resistant Tumor (2013)
  • Author(s): 異島 優
  • Organizer: AAPS Workshop on Drug Transporters in ADME
  • Place of Presentation: Bethesda North Marriott Conference Center, Bethesda MD, USA
• [Presentation] Poly-SNO-アルブミンによる抗癌剤耐性克服効果と機序解明 (2012)
  • Author(s): 異島優
  • Organizer: 日本薬学会
  • Place of Presentation: 北海道大学(北海道)
  • Year and Date: 2012-03-29
• [Presentation] ヒト血清アルブミンドメイン II によるビリルビン尿中排泄促進作用 (2012)
  • Author(s): 小田切 優樹 1,2,3)、蓑毛 藍 3)、異島 優 3)、 成底 徹 3)、 諏訪 喜昭 3)、渡邊 博志 3)、 森岡 弘志 3)、 丸山 徹3)
  • Organizer: 第28回日本 DDS 学会学術集会
  • Place of Presentation: 札幌コンベンションセンター(北海道)
• [Presentation] 高分子抗癌剤の腫瘍集積性を高める S -ニトロソ化アルブミンダイマーの EPR効果増強作用 (2012)
  • Author(s): 異島 優 1,2)、井上 亜希 1)、方 軍3)、前田 浩 4)、渡邊 博志 1,2)、小田切 優樹 1,3,4)、丸山 徹 1,2)
  • Organizer: 第28回日本 DDS 学会学術集会
  • Place of Presentation: 札幌コンベンションセンター(北海道)
• [Presentation] S-ニトロソ化に伴うα1-酸性糖タンパク質(AGP)の抗菌機能獲得と感染症治療への応用 (2012)
  • Author(s): 渡辺佳織 1, 異島 優 1, 2, 赤池孝章 3,澤 智裕 3, 黒田照夫 4, 小川和加野 4, 渡邊博志 1, 2, 甲斐俊哉 1, 5, 小田切優樹 1, 6, 7, 丸山徹 1, 2
  • Organizer: 第12回日本 NO 学会学術集会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] S-ニトロソ化アルブミンにより抗アポトーシス効果を付与した改良型臓器保存液の開発 (2012)
  • Author(s): 異島 優 1,2、 品川 拓也 1、 米重 梓二 1、 甲斐 俊哉 1、 赤池 孝章 3、 小田切 優樹 1,4,5、丸山 徹 1,2
  • Organizer: 第12回日本 NO学会学術集会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] S -ニトロソ化アルブミンダイマーはEPR 効果を増強する (2012)
  • Author(s): 3、 前田 浩 4、 小田切 優樹 1,3,4、渡邊 博志 1,2、 丸山 徹 1
  • Organizer: 日本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] ブレオマイシン誘発肺線維症に対するアルブミン-チオレドキシン融合体の有用性評価 (2012)
  • Author(s): 田中 遼大 1、 小玉 あずさ 1、 異島 優 1,2、 田中 健一郎 1、 水島徹 1、渡邊 博志 1,2、 小田切 優樹1,3,4、 丸山 徹 1,2
  • Organizer: 日本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] 新規翻訳後修飾体である S -グアニル化アルブミンは抗菌効果を発揮する (2012)
  • Author(s): 異島 優 1,2、 星野 瞳 1、 品川 拓也 1、 小田切 優樹 1,3,4、 渡邊 博志 1,2、丸山 徹 1,2
  • Organizer: 本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] アルギニンペプチドを利用した細胞膜透過型アルブミンの設計と評価 (2012)
  • Author(s): 濱崎 慶輔 1、 渡邊 博志 1,2、 弥永 直樹 1、 國安 明彦 3、 異島 優1,2、 小田切 優樹 1,3,4、 丸山 徹 1,2
  • Organizer: 日本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] ファージディスプレイ法を用いた尿毒症 物 質 3-carboxy-4-methyl-5-propyl-2-furan (CMPF)高親和性アルブミン変異体の設計 (2012)
  • Author(s): 西村 知晃 1、 蓑毛 藍 1、 異島 優1,2、 末永 綾香 1、 渡邊 博志 1,2、森岡 弘志 1、 小田切 優樹 1,3,4、 丸山 徹 1,2
  • Organizer: 日本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] In vivo ファージディスプレイ法を用いた新規腎送達ペプチドの探索 (2012)
  • Author(s): 弥永 直樹 1、 渡邊 博志 1,2、 濱崎慶輔 1、 國安 明彦 3、 異島 優 1,2、小田切 優樹 1,3,4、 丸山 徹 1,2
  • Organizer: 日本薬剤学会第27年会
  • Place of Presentation: 神戸国際会議場(兵庫県)
• [Presentation] p-Cresyl sulfate causes renal tubularcell damage by inducing oxidativestress through the activation of NADPHoxidaseHiroshi (2012)
  • Author(s): Hiroshi Watanabe1,2, Daisuke Honda1,Yohei Miyamoto1, Tsuyoshi Noguchi1,Daisuke Kadowaki1,2, Yu Ishima1,2,Motoko Tanaka3, Hisae Tanaka4,Masafumi Fukagawa4, Masaki Otagiri1,5and Toru Maruyama1,2
  • Organizer: 49th ERA-EDTA Congress, Paris 2012
  • Place of Presentation: Paris(France)
• [Presentation] A uremic toxin,3-carboxy-4-methyl-5-propyl-2-furanpropionate accumulates inproximal tubular cells and inducescell damage through increasingoxidative stress (2012)
  • Author(s): Yohei Miyamoto1, Yasunori Iwao2,Katsumi Mera1, Hiroshi Watanabe1,3,Daisuke Kadowaki1,3, Yu Ishima1,Victor Tuan Giam Chuang4, KeizoSato5, Masaki Otagiri1.6 and ToruMaruyama1,3*
  • Organizer: 49th ERA-EDTACongress, Paris 2012
  • Place of Presentation: Paris(France)
• [Presentation] 新規翻訳後修飾体であるS-グアニル化アルブミンは抗菌効果を発揮する (2012)
  • Author(s): 異島 優
  • Organizer: 日本薬剤学会第２７年会
  • Place of Presentation: 神戸国際会議場
• [Presentation] Human serum albumin-thioredoxin fusion protein is effective in suppressing reactive oxygen species involved in lung injury (2012)
  • Author(s): 異島 優
  • Organizer: 第33回内藤コンファレンス
  • Place of Presentation: シャトレーゼ ガトーキングダム サッポロ
• [Presentation] S-ニトロソ化アルブミンにより抗アポトーシス効果を付与した改良型臓器保存液の開発 (2012)
  • Author(s): 異島 優
  • Organizer: 第12回日本NO学会学術集会
  • Place of Presentation: 神戸国際会議場
• [Presentation] 高分子抗癌剤の腫瘍集積性を高めるS-ニトロソ化アルブミンダイマーのEPR効果増強作用 (2012)
  • Author(s): 異島 優
  • Organizer: 第28回日本DDS学会
  • Place of Presentation: 札幌コンベンションセンター
• [Presentation] SNO-Albumin Dimerによる腫瘍組織への高分子抗癌剤デリバリー制御 (2012)
  • Author(s): 異島 優
  • Organizer: 第2回DDS製剤臨床応用FG合宿討論会
  • Place of Presentation: 箱根（帝京大学合宿所）
  • Invited
• [Presentation] 高分子抗癌剤の腫瘍移行制御特性を有するSNO-Albumin Dimerの設計 (2012)
  • Author(s): 異島 優
  • Organizer: 創剤フォーラム
  • Place of Presentation: 徳島大学薬部長井記念ホール
• [Presentation] 一酸化窒素付加型アルブミンを用いた腫瘍組織への高分子抗癌剤デリバリー制御 (2012)
  • Author(s): 異島 優
  • Organizer: 崇城大学DDS研究所 第二回シンポジウム
  • Place of Presentation: 崇城大学薬学部
  • Invited
• [Presentation] ACUTE-PHASE PROTEIN ALPHA1-ACID GLYCOPROTEIN ACQUIRES ANTIBACTERIAL ACTIVITY THROUGH S-NITROSATION BY A NITRIC OXIDE-DEPENDENT MECHANISM (2011)
  • Author(s): Watanabe K
  • Organizer: 日本薬物動態学会
  • Place of Presentation: 広島国際会議場(広島県)
  • Year and Date: 2011-11-17
• [Presentation] 臓器移植保存液としてのs-ニトロン化アルブミンの有用性評価 (2011)
  • Author(s): 品川拓也
  • Organizer: 日本血液代替物学会
  • Place of Presentation: 北海道大学(北海道)
  • Year and Date: 2011-10-27
• [Presentation] Poly-SNO-アルブミンによる抗癌剤耐性克服効果 (2011)
  • Author(s): 異島優
  • Organizer: 日本DDS学会
  • Place of Presentation: 東京大学(東京都)
  • Year and Date: 2011-06-10
• [Presentation] Mono-SNO-HSAとPoly- SNO-HSAによる細胞内NO輸送機構の解明 (2011)
  • Author(s): 異島優
  • Organizer: 日本NO学会
  • Place of Presentation: 昭和薬科大学(東京都)
  • Year and Date: 2011-05-13
• [Presentation] 臓器障害に対する各種S-ニトロソ化ヒト血清アルブミンの保護効果 (2010)
  • Author(s): 米重梓二
  • Organizer: 第25回日本薬物動態学会年会
  • Place of Presentation: 大宮ソニックシティ(埼玉県)
  • Year and Date: 2010-10-08
• [Patent(Industrial Property Rights)] 腎臓集積性を示すペプチド、薬物 (2012)
  • Inventor(s): 渡邊博志
  • Industrial Property Rights Holder: ニプロ株式会社
  • Industrial Property Number: 2012-097763
  • Filing Date: 2012-04-23
• [Patent(Industrial Property Rights)] 細胞膜透過性を有する製剤、細胞膜透過性組成物及び薬物輸送方法 (2012)
  • Inventor(s): 渡邊博志
  • Industrial Property Rights Holder: ニプロ株式会社
  • Industrial Property Number: 2012-097762
  • Filing Date: 2012-04-23
• [Patent(Industrial Property Rights)] 腎臓集積性を示すペプチド、薬物担体、製剤、医薬組成物 (2012)
  • Inventor(s): 渡邊博志
  • Industrial Property Rights Holder: ニプロ株式会社
  • Industrial Property Rights Type: 特許
  • Industrial Property Number: 2012-097763
  • Filing Date: 2012-04-23
• [Patent(Industrial Property Rights)] S-ニトロソ化α1-酸性糖タンパク質を含有する抗菌剤 (2011)
  • Inventor(s): 異島 優
  • Industrial Property Rights Holder: ニプロ株式会社
  • Filing Date: 2011-05-23
• [Patent(Industrial Property Rights)] 抗癌剤増感剤 (2011)
  • Inventor(s): 異島 優
  • Industrial Property Rights Holder: ニプロ株式会社
  • Filing Date: 2011-03-29
• [Patent(Industrial Property Rights)] S-ニトロン化α1-酸性糖タンパク質を含有する抗菌剤 (2011)
  • Inventor(s): 異島優
  • Industrial Property Rights Holder: ニプロ株式会社
  • Filing Date: 2011-10-29
• [Patent(Industrial Property Rights)] 抗癌剤増感剤 (2011)
  • Inventor(s): 異島優
  • Industrial Property Rights Holder: ニプロ株式会社
  • Filing Date: 2011-03-29
• [Patent(Industrial Property Rights)] 高リガンド親和性アルブミン変異体の製造方法 (2010)
  • Inventor(s): 異島 優
  • Industrial Property Rights Holder: 異島 優
  • Patent Publication Number: 2010-172277
  • Acquisition Date: 2010-08-12
• [Patent(Industrial Property Rights)] 高リガンド親和性アルブミン変異体の製造方法 (2010)
  • Inventor(s): 異島優
  • Industrial Property Rights Holder: ニプロ株式会社
  • Patent Publication Number: 2010-172277
  • Acquisition Date: 2010-08-12